BioMarin estimates that top line product revenue will grow approximately 20% to 25% in 2010 and approximately 15% to 20% in 2011. These revenue estimates reflect growth from existing commercial products and do not include potential sales from additional new products. BioMarin expects GAAP net income in the range of $35 million to $40 million in 2010 and in the range of $60 million to $65 million in 2011. Excluding stock compensation expense, non-GAAP net income is projected to be in the range of $70 million to $80 million in 2010 and in the range of $95 million to $105 million in 2011. These estimates are based on BioMarin's current business plan and do not include the effect of any significant business development transaction that the company may choose to do in the future.
Non-GAAP Financial Information and Reconciliation
The above results for the fourth quarter and full year of 2007 and 2008
and financial guidance for 2009, 2010 and 2011 include actual and Management's
2009, 2010 and 2011 estimated net income, respectively, determined in
accordance with GAAP and non-GAAP net income. As used in this release,
non-GAAP income is net income calculated in accordance with GAAP, but
excluding non-cash stock compensation expense, a non-GAAP financial measure.
Stock compensation expense excluded in the calculation of non-GAAP net income
was $7.4 million for the fourth quarter of 2008, $5.5 million for the fourth
quarter of 2007
|SOURCE BioMarin Pharmaceutical Inc.|
Copyright©2009 PR Newswire.
All rights reserved